β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction

By sjmartinez • May 22, 2024

LaFon DC, Helgeson ES, Lindberg S, Voelker H, Bhatt SP, Casaburi R, Cassady SJ, Connett J, Criner GJ, Hatipoglu U, Kaminsky DA, Kunisaki KM, Lazarus SC, McEvoy CE, Reed RM, Sciurba FC, Stringer W, Dransfield MT. β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction. JAMA Netw Open. 2024 May 1;7(5):e247535. doi: 10.1001/jamanetworkopen.2024.7535. PMID: 38771577.

Tags: Harbor UCLA, Publications, Pulmonary, Critical Care & Sleep Medicine

Population health strategies for health equity in chronic kidney disease management

Brown CO, Pham PC, Shah A, Dukkipati R, Shen J, Dai T, Raff EA, Kalantar-Zadeh K. Population health strategies for health equity in chronic kidney[...]

Semaglutide and kidney function: direct kidney protection or an artifact?

Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Walther FJ, Waring AJ. Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant. Am J Physiol Lung Cell Mol Physiol. 2024 Dec 1;327(6):L883-L889.[...]